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ABSTRAK
Kasus progressive multifocal leukoencephalopathy (PML) jarang terjadi, tapi berakibat fatal yang 
menyebabkan gangguan neurologi yang berat. PML merupakan suatu manifestasi klinis yang biasanya berkaitan 
dengan infeksi virus John Cunningham (JC). PML juga berhubungan dengan kondisi keganasan, terutama 
keganasan hematologi, misalnya leukemia limfositik kronik.Sampai saat ini belum ada terapi yang tepat untuk 
PML yang diakibatkan virus JC, sehingga prognosis pada penderita ini sangat buruk.
Laporan kasus ini menyajikan suatu kasus yakni wanita berusia 67 tahun yang menderita LLK dengan 
keluhan utama kejang. Gejala klinis pasien, hasil MRI kepala serta hasil biopsi otak mendukung diagnosis PML 
akibat virus JC. Pasien mendapatkan terapi mefloquine 250 mg/hari, tetapi tidak mengalami perbaikan klinis.
Kata kunci: progressive multifocal leukoencephalopathy (PML), virus John Cunningham, leukemia limfositik 
kronik (LLK).
ABSTRACT
Progressive multifocal leukoencephalopathy (PML) is a rare but fatal disease leading to severe neurological 
impairments. PML is a clinical manifestation, which is usually associated with John Cunningham virus (JCV) 
infection. It is also correlated to malignancies that mainly include hematologic malignancies such as chronic 
lymphocytic leukemia (CLL). Until now, no specific treatment has been established for JCV-induced PML; 
therefore, the prognosis of this disease is poor.
We present a case of a 67-year-old woman who suffered from CLL with a chief complaint of seizure. Her 
clinical symptoms, results of brain MRI and biopsy were suggestive for the JCV-induced PML. The patient had 
received treatment using mefloquine at dose of 250 mg/day with no clinical improvement.
Keywords: progressive multifocal leukoencephalopathy (PML), John Cunningham virus, chronic lymphocytic 
leukemia (CLL).
INTRODUCTION
Chronic lymphocytic leukemia (CLL) 
is a lymphoproliferative disorder, which is 
characterized by clonal proliferation and 
accumulation of malignant B cell lymphocytes in 
the bone marrow, vascular and lymphoid tissue.1 
Like other malignancies, infection is still the 
main reason for high morbidity and mortality rate 
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in patients with CLL. The infection, particularly 
viral infection, may lead to CLL-associated 
immune dysfunction.2
John Cunningham Virus (JCV) belongs to 
the Polyomaviridae family. In 1971, the virus 
was first isolated from the brain tissue of a 
patient with Hodgkin disease.3 JCV is commonly 
found in community and causes infection in 70-
90% human population, which usually occurs 
in childhood and adolescence. JCV is more 
common in urban than rural areas since high 
concentration of JVC has been widely found 
in the sewage of different cities. Contaminated 
water could be potential source of JCV infection.4
JCV causes PML (Progressive Multifocal 
Leukoencephalopathy) and it mostly occurs in 
immunodeficient condition such as in patients with 
AIDS (Acquired Immune Deficiency Syndrome) 
or patients receiving immunosuppressant 
treatment. PML is a rare but fatal disease as it 
causes central nervous system disorder, which 
is characterized by neuron demyelinization 
leading to severe neurologic impairment.5 The 
disease is commonly associated with malignancy, 
particularly with hematological malignancies 
such as Hodgkin Lymphoma, Non-Hodgkin 
Lymphoma, CLL, myeloma, Waldenstrom 
Macroglobulinemia and patients undergoing 
hematopoietic stem cell transplantation (HSCT).6 
A retrospective study evaluating CLL patients 
from January 2000 until June 2008 found 
that PML incidence is approximately 11.1 per 
100,000 person year.7
CASE ILUSTRATION
A 67-year-old female patient was admitted 
to our emergency department with a chief 
complaint of recurrent convulsion  since 3 days 
prior to admission. She had been diagnosed 
with CLL since 8 years ago and had received 
chlorambucil for her treatment. In the previous 
3 months, she complained about memory loss 
and right-sided weakness. She was then admitted 
to a hospital and diagnosed with stroke and 
lymphoma. She had progressive weakness in 
spite of the treatment that she had received. In 
addition to her weakness, she also had slurred 
speech, confusion and sleepiness.
Multiple magnetic resonance imaging (MRI) 
was performed and we noted increased signal 
intensity in the white matter of both left and 
right occipital lobes, which was observed on 
T2-weighted MRI scan. The left side had worse 
condition as the increased signal intensity had 
been extended forwards into the left temporal 
lobe and downwards into left thalamus. Low 
signal intensity was observed on T1-weighted 
MRI scan and no enhancement was noted in the 
contrast-enhanced MRI.
Brain biopsy of the left occipital lesion was 
performed and it showed bizarre-shaped astrocytes, 
foamy macrophages, enlarged oligodendrocytes, 
perivascular lymphocyte aggregation. The rare 
macrophages were engulfed by myelin debris and 
the oligodendrocyte nuclei in the white matter 
were stained positive for polyomavirus. Based on 
her clinical symptoms, results of brain MRI and 
biopsy, a diagnosis of JCV-induced progressive 
multifocal leukoencephalopathy (PML) was made 
and the patient received mefloquine treatment 
at the dose of 250 mg/day. The patient was then 
admitted to the intensive care unit (ICU). In the 
ICU, she was on anti-convulsion medication and 
the mefloquine treatment was stopped. She never 
had convulsion again, but she became coma over 
the following one months. Then the patients 
came home forcibly from the hospital, and used 
a portable respirator for approximately 2 months, 
and finally the patients died at home.
DISCUSSION
CLL occurs more common in men than 
women and the average age at the time of 
diagnosis is around 65 years with only 10-
15% cases occur in patients aged less than 50 
years.8 Most CLL cases are asymptomatic and 
the diagnosis is usually made accidentally by 
laboratory examination.1,9,10 The diagnostic 
criteria for CLL according to International 
workshop for CLL and National Cancer Institute 
include the increased absolute lymphocyte 
count of more than 5 x 109/L (5000/µL) in 
peripheral blood with specific morphology and 
immunophenotypes. To confirm the diagnosis, 
a peripheral blood smear must be performed. 
The blood smear will then reveal lymphocytosis 
with a dominance of mature small lymphocytes 
and smudge cells. The diagnosis of CLL can 
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be confirmed when there are more than 30% of 
nucleated cells in the bone marrow aspirate.1,10 
Once the diagnosis of CLL has been confirmed, 
we should perform staging to predict prognosis 
and determine appropriate treatment.
Treatment should be given at symptomatic or 
progressive intermediate stage.10,11 The first-line 
treatment for CLL includes a single chemotherapy 
using alkylating agents (chlorambucyl or 
cyclophosphamide). Combination chemotherapy 
is reserved for patients who had failed to 
respond to treatment using chlorambucyl 
or cyclophosphamide alone either with or 
without prednisone, which include COP 
(cyclophosphamide, vincristine and prednisone). 
While the second-line treatment includes purine 
analogs (fludarabine) or monoclonal antibody 
(rituximab or alemtuzumab).10,12
History taking of our patient reveals that 
she has had a diagnosis of CLL since 8 years 
ago and has received single chemotherapy 
using an alkylating agent, i.e. chlorambusil. 
The patient has a risk factor for infection due 
to her immunodeficient condition, which may 
be caused by either the disease itself or by 
the effect of chemotherapy. CLL is usually 
found together with immune dysfunction 
that may lead to multiple complications. 
Any defect in cell-mediated immune system 
including abnormal number or function of 
B-cell lymphocytes, T lymphocytes, Natural 
Killer (NK cells), neutrophils and abnormal 
monocytes or macrophages or defect in humoral 
immune response such as low titer of gamma 
globulin has been considered to have some roles 
in the development of multiple complications 
in patients with CLL.2,13 The complications 
particularly affect central and peripheral nervous 
systems, which are the target organ for CLL-
related complications and serious consequences 
may occur.14
John Cuningham Virus (JCV) is a double-
stranded DNA virus. It belongs to human 
polyomavirus family, which is also known as 
papovavirus. The virus genetically resembles 
BKvirus and SV40. It was first identified using 
electron microscope in 1965 by Zurhein and 
Chou and subsequently cultured by Silverman 
and Rubinstein. The virus was named after 
the first patient who was diagnosed with 
PML.7,15 Epidemiological studies show that 
JCV affects approximately 75-80% human 
population and half of the infection cases occur 
during childhood. Primary infecton is usually 
asymptomatic and 85% of adult population 
usually have have antibody against JCV. The 
virus infiltrates human body through inhalation 
or oral route from water contaminated with urine 
or fecal material from infected individual. After 
the infiltration, JCV will develop local infiltration 
in tonsillar stromal cells and lymphocytes or in 
the upper and lower gastrointestinal tract, which 
may serve as the initial site of viral infection. 
Viral replilcation then takes place in tonsillar and 
intestinal lymphoid tissue. It may become a latent 
infection and being dormant in some of body 
parts such as tonsil, kidney, lymphoid tissue, and 
bone marrow.16-19 Reactivation of latent infection 
usually occurs in kidney and brain tissue.19
Cellular immune response has a role of 
defense mechanism against JCV infection. 
CD4 T-helper cells recognize virus particle and 
stimulate CD8 T-cytotoxic cells to eliminate the 
virus. In patients with CLL, there are changes 
of gene expression in T cells. In CLL patients 
there was a change in gene expression in T 
Table 1. Staging system according to Rai and Binet for CLL 1
Binet stages Rai stages Median survival
Low risk A Hb ≥ 10, platelets ≥ 100 000, ≤ 2 
sites involved 
0
Lymphocytosis in blood and bone 
marrow > 10years
Intermediate risk B Hb ≥ 10, platelets ≥ 100 000, ≥ 3 
sites involved
I Lymphocytosis + lymphoadenopathy 5-7 years
II Lymphocytosis + splenomegaly and/
or hepatomegaly
High risk C Hb < 10, or platelets < 100 000 III Lymphocytosis + Hb <11.0 < 3-4 years
IV Lymphocytosis + platelets < 100 000
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lymphocyte. In particular, there is a failure in 
CD4 as well as CD8 T cell differentiation into 
Th1 subsets; therefore, the patients are more 
susceptible to have viral infection.6 In addition, 
the B cells of patients with CLL also TGF-β, 
which has an immunosupressive role that can 
cause blocking of lymphocyte proliferation and 
activation as well as blocking of macrophage 
activation.9
Severe T-cell (cellular) immune deficiency is 
associated with reactivation of JCV. Suppressed 
cellular immune response due to HIV infection 
is the main reason of JCV reactivation and 
it occurs in 80% of patients with PML. It 
also can occur in patients with hematologic 
malignancy (14%), with transplantation (5%) or 
patients with autoimmune disease who receive 
immunomodulator therapy (3%).
Epidemiological studies have demonstrated 
that PML is a clinical manifestation, which is 
often associated with JCV infection.3 PML or 
progressive multifocal leukoencephalopathy is a 
neurologic abnormality characterized by myelin 
damage or demyelination of the central nervous 
system, which is induced by JCV. PML has a 
slow progression and it gets worse leading to 
severe brain damage resulting in death within 
4 to 6 months; while sometimes, it may remain 
stagnant. 
 Leukoencephalopathy in PML abbreviation 
indicates that it generally attacks brain, 
particularly the subcortical white matter and 
mostly affects parietal and occipital lobes; 
however, in some cases, it may also attack the 
gray matter.
Although demyelination can occur in every 
part of the white matter, but it also can occur in 
the brain stem and cerebellum. In general, it is a 
multifocal process.5,7 Visual defect is a common 
symptom and it can be found in approximately 
35 to 45% cases. Cognitive impairment including 
unstable emotion, memory loss and dementia may 
occur in one third of cases. Motor weakness can 
be found in 25 to 33% cases and other symptoms 
may also appear including speech difficulty and 
convulsion.5,7,20 PML has a wide variation of 
clinical presentation, which can be difficult to 
diagnose or to differentiate it with other diseases 
such as ischemic brain disease, vasculitis, brain 
neoplasma (glioma or lymphoma), central 
nervous system infection (HIV encephalopathy, 
herpes simplex encephalopathy, neurosyphilis).21 
In our patient, we found several symptoms 
including right-sided hemiparesis, speech 
problem, sleepiness and confusion. Later, the 
patient had multiple recurrent seizures and was 
diagnosed with stroke and brain lymphoma. 
However, no improvement was seen although 
she was on treatment and her condition worsened 
with poor prognosis. Her laboratory work-up 
showed the following results: non-reactive 
syphilis TP antibody test, non-reactive anti HIV 
test, non-reactive IgM and IgG toxoplasma, 
which suggest that infection of central nervous 
system could be excluded.
The association between JCV infection 
and PML was first reported by Padgett et al in 
1971. JCV was isolated from a PML patient 
in a postmortem examination.22 JCV can be 
found in B cell lymphocytes from the peripheral 
circulation (hematogenous infiltration) and 
it may further infiltrate the central nervous 
system by penetrating blood brain barrier. 
The lymphocytes later eject virion and infect 
oligodendrocytes as well as astrocytes. The 
mechanism possibly occurs through 5-HT2A 
serotonin receptor.23,24 Oligodendrocyte is a 
myelin producting cell in the central nervous 
system and it is the main target of JCV infection. 
JCV can also attack astrocytes, which causes 
astrocytes to swell, to have lobulated nuclei 
and to take bizarre shape, which is similiar to 
nuclear structure.5 PML case was first reported 
in patients with CLL and Hodgkin disease in 
1958.3 Although PML usually occur in patients 
with HIV, but 15% cases occur in individuals 
with lymphoproliferative disorders (LPDs) 
including patients with CLL, CML, and Hodgkin 
disease. Before 1989, LPDs-associated PML was 
reported mainly in patients with  Hodgkin disease 
(63%) who receive alkylating agents therapy 
(monotherapy or combination therapy) and/or 
radiation. Since 1989, LPDs-associated PML 
more likely occurs in patients with CLL (46%) 
than those with Hodgkin disease (25%). Later, 
the paradigm of treatment for CLL and other 
lymphoproliferative disease was shifted to purine 
analogs and rituximab.22 Over the last decades, 
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the standard regimen for CLL treatment includes 
chlorambucil, an alkylatin agent, which is usually 
given as a monotherapy or a combination therapy 
with steroids.2 When using the treatment, most 
patients usually experiences bacterial infection 
such as Staphylococcus aureus, Streptococcus 
pneumonia, Haemophilus influenza and gram-
negative bacteria in the intestine. It is also 
associated with infection due to mucosal bacteria 
such as airway tract infection and the infection 
is usually recurrent. The conventional alkylator-
based therapies is rarely associated with fungal or 
viral infection.2 The risk factor of having infection 
in our patient may be due to the following reason, 
i.e. she was a patient with CLL, which means 
that she had immunocompromised status since 
she also received immunosuppressant therapy 
(chlorambucil). Moreover, she had a history of 
using corticosteroid treatment, which put her into 
a higher risk for infection. When she received 
treatment using alkylating agent (chlorambucil), 
she suffered from diarrhea, recurrent respiratory 
tract infection, Herpes Zoster infection and 
ultimately, JCV infection.
The diagnosis of PML was made based on 
clinical manifestations, laboratory findings and 
results of radiological examination as well as 
histopathological examination. Radiological 
examination has an important role in diagnosis 
and in the follow up of JCV infection. Magnetic 
resonance imaging (MRI) may demonstrate 
multifocal lesions without any contrast 
enhancement or mass effect. Hypointense 
signal can be found in T1-weighted MRI scan; 
while hyperintense signal may be prominent in 
the T2-weighted MRI scan when the results are 
compared to the images of normal white matter. 
The lesion is particularly predominant in the white 
matter of periventricular, subcortical frontal and 
parieto-occipital areas. The distribution of lesion 
is usually asymetric, diffuse, subcortical and it is 
localized in the white matter. The CT scan may 
reveal focal or multifocal lesion without any 
enchancement or mass effect.3,7,25
The MRI of our patient revealed a 
hyperintense signal in the white matter of both 
left and right occipital lobes, which was observed 
on T2-weighted MRI scan.The signal was more 
intense in the left side hemisphere and the 
intensity extended to anterior into left temporal 
lobe and left thalamus; while hypointense signal 
was found in T1-weighted MRI scan and the non-
absorbed contrast lesion, which characterized the 
signs of PML. The course of the disease later 
showed that the lesion extended to brain stem 
(Figure 1).
Detection of JCV DNA by PCR can be 
performed using specimens from cerebrospinal 
fluid (CSF) or brain biopsy. PCR using CSF 
specimen has 74% to 93% sensitivity and 92% 
to 99% specificity; while when using brain 
biopsy, the test has 64% to 96% sensitivity and 
100% specificity.7 The risk of complication is 
2.9% and the morbidity rate is 8.4%. Stereotactic 
brain biopsy is a standard diagnostic procedure 
for PML.
On histopathlological examination, we 
can observe single or multiple demyelination 
area containing JCV-infected oligodendrocytes 
with enormous nuclei found at the periphery of 
Figure 1. Results of imaging in a patient with PML
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the lesion and reactive gliosis, bizarre-shaped 
astrocytes, lipid-laden macrophages, which 
phagocyte myelin, and cellular debris.3,7 The 
JC virus genome and protein expression can 
be detected using in situ hybridization and 
immunohistochemistry.26
In our patient, we performed a MRI-guided 
stereotactic brain biopsy for her left occipital lobe 
lesion (Figure 2). The biopsy revealed bizzare-
shaped astrocytes, foamy macrophages, enlarged 
oligodendrocytes, aggregation of perivascular 
lymphocytes, rare macrophages with engulfed 
myelin debris. The oligodendrocytes in the white 
matter were stained positive for polyomavirus, 
which indicates that the patient was reactive to 
JCV test. The test was performed in Canada; 
therefore, based on her clinical signs and 
symptoms as well as the results of imaging and 
histopathological examination, the patient was 
diagnosed with definite PML.
There was no specific treatment for JCV 
infection. The main approach of our strategy was 
to restore the patient’s adaptive immune system 
as it may improve her survival.26 In HIV-negative 
patients, immunosuppressant treatment is usually 
stopped. There are several specific regimens 
for eliminating JCV, which include cytarabine, 
cidofovir and topotecan, which have been used 
in some clinical trials; however, no clinical 
advantage has been demonstrated. Moreover, 
some toxicities and side effects of the treatment 
should be carefully considered.3 Treatment 
using 5-HT2a serotonin receptor antagonists 
(risperidone and mirtazapine), which block 
infection of glial cells by JCV may be useful for 
treating PML; however, further studies should 
be conducted to provide sufficient evidences.27,28 
In June 2010, a study first reported that a 
PML patient had a successful treatment using 
mefloquine. Mefloquine is an anti malaria drug 
that works against JCV infection. The drug can 
probably eliminate virus and thus prevent further 
neurological damage; however, recent studies 
have not demonstrated any significant result.29,30
After our patient had been diagnosed with 
PML, the immunosuppressant medication 
including chlorambucil was stopped so that the 
patient could have a recovery of her immune 
system. Moreover, mefloquine was given to 
overcome her JCV infection; however, no 
Table 2. Diagnostic criteria for PML3
Diagnosis Clinical features Imaging features JCV DNA in CSF Typical Histopathological Features with a Demonstration of JCV DNA
Definite PML + + + -
Definite PML + + - +
Presumptive PML + + - _
Figure 2. MRI-guided stereotactic brain biopsy for left occipital lobe lesion
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clinical improvement was seen. The mortality 
rate of LPDs-associated PML mortality rate 
is more than 90%.22 The disease has a rapid 
clinical progression and when it is not treated 
immediately, the median overall survival is 
approximately 3.5 month.31 Until now there is 
no specific treatment available for JCV-induced 
PML; therefore, the prognosis is poor.7 The 
clinical condition of our patient got worse and 
thus her prognosis was also bad.
CONCLUSION
Progressive multifocal leukoencephalopathy 
(PML) is a neurologic abnormality, which is 
characterized by myelin damage (demyelinationi) 
of the central nervous system and it is associtated 
with JCV infection. Our main strategy was to 
restore the patient’s adaptive immune system. 
Until now there is s no specific treatment for 
JCV-induced PML; therefore, the prognosis of 
the disease is poor.
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